Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Ralph Defronzo
University of Texas Hlth Science Center, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
AstraZeneca
Payment for services (e.g., consulting fees, honoraria, paid authorship)
AstraZeneca will provide the study drug at no cost. A conflict of interest is created as a result of Dr. DeFronzo's service on the AstraZeneca Scientific Advisory Board. There are no deliverable required to be provided to AstraZeneca as a condition of receiving the study drug at no cost. Dr. DeFronzo will provide quarterly enrollment totals to AstraZeneca as a courtesy but not any additional data.
Durability of Early Combination Therapy vs Conventional Therapy in New Onset T2DM
In the currently ongoing Triple Therapy Study, we demonstrated that initiating therapy in newly diagnosed type 2 diabetic subjects with combination pioglitazone/metformin/exenatide therapy compared to the more conventionally recommended approach (start with metformin, then add a second oral agent [sulfonylurea], and then add to basal insulin) produces superior glycemic control. The difference in HbA1c between the two arms at 3 years was -0.75%, with 7-fold lower risk of hypoglycemia, mean weight loss as opposed to weight gain, decrease in blood pressure, and marked improvements in insulin sensitivity and beta cell function. The aim of the present grant proposal is to extend the follow-up to additional 3 years to examine the long term durability of the metabolic benefits of the combination therapy.
Filed on October 26, 2015.
Tell us what you know about Ralph Defronzo's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Ralph Defronzo filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
| Ralph Defronzo | University of Texas Hlth Science Center | Conflict of Interest | AstraZeneca | $100,000 - $149,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.